RSS-Feed abonnieren
DOI: 10.1055/s-0038-1648158
Stimulation of Plasmin Activity by Aspirin
Publikationsverlauf
Received: 08. Mai 1990
Accepted after revision 16. November 1990
Publikationsdatum:
02. Juli 2018 (online)
![](https://www.thieme-connect.de/media/10.1055-s-00035024/199104/lookinside/thumbnails/10-1055-s-0038-1648158-1.jpg)
Summary
This study demonstrates an enhancing effect of aspirin on the amidolytic activity of plasmin. The stimulation of plasmin by aspirin was concentration-dependent and was attained at aspirin concentrations above 2 × 10−4 M. Aspirin produced a small, reproducible and statistically significant stimulation of the chromogenic activity of plasmin upon H-D-Valyl-L-Leucyl-L-Lysine-p-nitroanilide (3-2251) or pyro-Glu-Gly-Arg-p-nitroanilide (S-2444). Kinetic analysis demonstrated a slight decrease in the affinity of plasmin for substrate 3-2251 in the presence of aspirin, reflected by a change of the Km from 3.2 × 10-4 M to 3.8 × 10-4 M, and an increase of the Vm. The reciprocal Lineweaver-Burk curve indicated an uncompetitive type of stimulation. The stimulatory effect of aspirin was abolished by the lysine analogue α-aminohexanoic acid (AHA) but not by the α-amino acid glutamic acid. The effect of AHA suggests a specific involvement of lysine binding sites (LBS) on plasmin in the interaction of the enzyme with aspirin. Tlansient acidification of plasmin abolished its response to aspirin, to AHA and to their combination. The addition of aspirin to diluted human control or pregnancy plasma in vitro stimulated the plasma-mediated cleavage of the chromogenic substrate3-2251. In contrast to its effect on plasmin, aspirin failed to change the activity of tissue-type or urokinasetype plasminogen activators. It is conceivable that in addition to the antithrombotic effect of aspirin ascribed to its interaction with the platelets, aspirin also directly stimulates plasmin activity.
-
References
- 1 Collen D. Molecular mechanisms of fibrinolysis and their application to fibrin-specific thrombolytic therapy. J Cell Biochem 1987; 33: 77-86
- 2 Saksela O, Rifkin DB. Cell-associated plasminogen activation: Regulation and physiological functions. Annu Rev Cell Biol 1988; 4: 93-126
- 3 Dano K, tsehrendt N, Lund LR. et al Cell surface plasminogen activation. In: Cancer Metastasis: Molecular and Cellular Biology, Host Immune Responses and Perspectives for Tieatment Schirrmacher Y, Schwartz-Albiez R. eds Springer Verlag; Berlin: 1989: 98-107
- 4 Mayer M. Biochemical and biological aspects of the plasminogen activation system. Clin Biochem 1990; 23: 197-211
- 5 Lijnen HR, Collen D. Molecular mechanisms of thrombolytic therapy. Haemostasis 1986; 16 (Suppl. 03) Suppl 3-15
- 6 Markus G, De Pasquale JL, Wissler FC. euantitative determination of the binding of epsilon-aminocaproic acid to native plasminogen. J Biol Chem 1978; 253: 727-732
- 7 Collen D. On the regulation and control of fibrinolysis. Thromb Haemostas 1980; 43: 77-89
- 8 Rickli EE, Otavski WI. A new method of isolation and some properties of heavy chain of human plasmin. Eur J Biochem 1975; 59: 441-447
- 9 Wiman B, Collen D. On the kinetics of the reaction between human antiplasmin and plasmin. Eur J Bioch em 1978; 84: 573-578
- 10 Higazi A, Mayer M. Inhibition of plasmin by fibrinogen. Biochem J 1990; 269: 299-302
- 11 Higazi A, Mayer M. Effects of penicillins and β-aminohexanoic acid on the kinetics of human plasmin. Biochem J 1989; 260: 609-612
- 12 Ranby M, Brandstrom A. Biological control of tissue plasminogen activator-mediated fibrinolysis. Enzyme 1988; 40: 130-143
- 13 Moroz LA. Increased blood fibrinolytic activity after aspirin ingestion. N Engl J Med 1977; 296: 525-529
- 14 Louie S, Gurewich V. The antithrombotic effect of aspirin and dipyridamole in relation to prostaglandin synthesis. Thromb Res 1983; 30: 323-345
- 15 Fuster V, Cohen M, Halperin J. Aspirin in the prevention of coronary disease. N Engl J Med 1989; 321: 183-185
- 16 Green D, Davies Ro, Holmes GI, Johnson C, Kohl H, Reynolds N, Tsio C-H. Fibrinolytic activity after administration of diflunisal and aspirin. Haemostasis 1983; 13: 394-398
- 17 Cattaneo M, Chahil A, Somers D, Kinlough-Rathbone RL, packham MA, Mustard JE. Effect of aspirin and sodium salicylate on thrombosis, fibrinolysis, prothrombin time and platelet survival in rabbits with indwelling aortic catheters. Blood 1983; 6l: 353-361
- 18 Levin RI, Harpel PC, weil D, Chamg T-S, Rifkin DB. Aspirin inhibits vascular plasminogen activator activity in vivo. Studies utilizing a new assay to quantify plasminogen activator activity. J Clin Invest 1984 74. 571-580
- 19 Boumnameaux H, Gresele P, Hanss M, De Cock E, vermylen J, Collen D. Aspirin, indomethacin and dazoxiben do not affect the fibrinolytic activation induced by venous occlusion. Thromb Res 1985; 40: 161-170
- 20 Hammouda MW, Moroz LA. Aspirin and venous occlusion: Effects on blood fibrinolytic activity and tissue:type plasminogen activator ievels. Thromb Res 1986; 42: 73-82
- 21 De Gaetano G, Carriero MR, Cerletti C, Moussoni L. Low-dose aspirin does not prevent fibrinolytic response to venous occlusion. Biochem Pharmacol 1986; 35: 3147-3150
- 22 Levin RI, Harpel PA, Harpel JG, Recht PA. Inhibition of tissue plasminogen activator activity by aspirin in vivo and its relationship to levels of tissue plasminogen activator antigen, plasminogen activator inhibitor, and their complexes. Blood 1989; 74: 1635-1643
- 23 Beaufils M, Donsimoni R, llzam S, Colan JC. prevention of preeclampsia by early antiplatelet therapy. Lancet 1985; i: 840-842
- 24 Wallenburg HCS, Makovitz JW, Dekker GA, Rotmans O. Low-dose aspirin prevents pregnancy-induced hypertension and preeclampsia in angiotensin sensitive primigravidae. Lancet 1986; i: 1-3
- 25 Wallenberg HCS, Rotmans N. Prevention of recurrent idiopathic fetal growth retardation by low-dose aspirin and dipyridamole. Am J Obstet Gynecol 1987; 157: 1230-5
- 26 Trudinger BJ, Cook CM, Thompson RS. et al Low-dose aspirin therapy improves fetal weight in umbilical placental insufficiency. Am J Obstet Gynecol 1988; 159: 681-685
- 27 Schiff E, Peleg E, Goldenberg M, Rosenthal I, Ruppin E, Thmarkin M, Barkai G, Ben-Baruch G, Yahal I, Blankstein J, Goldmatr B, Mashiach S. The use of aspirin to prevent pregnancy-induced hypertension and lower the ratio of thromboxane A2 to prostacyclin in relatively high-risk pregnancies. N Engl J Med 1989; 321: 351-356
- 28 Sibai BH, Mirro R, Chesney CM, Leffler C. Low-dose aspirin in pregnancy. Obstet Gynecol 1989; 74: 551-557
- 29 Ylikorkala O, Pekonen E, Viinikka L. Renal prostacyclin and thromboxane in normotensive and preeclamptic pregnant women and their infants. J Clin Endoc Met 1986; 63: 1307-1312
- 30 Fitzgerald DJ, Rocki W, Murray R, Mayo G, Fitzgerald GA. Thromboxane A2 synthesis in pregnancy-induced hypertension. Lancet 1990; 335: 751-754
- 31 Deutsch DG, Mertz ET. Plasminogen: Purification from human plasma by affinity chromatography. Science 1970; 170: 1095-1096
- 32 Yioland BN, Byrne R, Castellino EI. The effect of alpha-, omegaamino acids on human plasminogen structure and activation. J Biol Chem 1978; 253: 5395-5401
- 33 Wiman B, Collen D. Molecular mechanism of physiological fibrinolysis. Nature 1978; 272: 549-550
- 34 Thorsen S. Differences in the binding to fibrin of native plasminogen and plasminogen modified by proteolytic degradation. Influence of omega-aminocarboxylic acid. Biochim Biophys Acta 1975 393. 55-65
- 35 Wiman B, Wallen P. The specific interaction between plasminogen and fibrin. A physiological role of the lysine binding site in plasminogen. Thromb Res 1977; 11: 213-222
- 36 Saksela O. Plasminogen activation and regulation of pericellular proteolysis. Biochim Biophys Acta 1985; 823: 35-65
- 37 Rijken DC, Groeneveld E. Isolation and functional characterization of the heavy and light chains of human tissue-type plasminogen activator. J Biol Chem 1986; 261: 3098-5102
- 38 Vaugham De, Declerck PJ, DE Mol M, Collen D. Recombinant plasminogen activator inhibitor-l reverses the bleeding tendency associated with the combined administration of tissue-type plasminogen activator and aspirin in rabbits. J Clin Invest 1989; 84: 586-591
- 39 Loscalzo J, Vaugham DE. Tissue plasminogen activator promotes platelet disaggregration in plasma. J Clin Invest 1987; 79: 1749-1755
- 40 De Gaetano G, Cerletti C, Dejana E, Latini R. Pharmacology of platelet inhibition in humans: Implications of the salicylate-aspirin interaction. Circulation 1985; 72: 1185-1593
- 41 Astedt B, Isacsoil S, Nilsson IM. Fibrinolytic activity of veins during pregnancy. Acta Obstet Gynecol Scand 1970; 49: 171-173
- 42 Wiman B, Csemiczky G, Marsk L, Robbe H. The level of fast inhibitor of tissue plasminogen activator in plasma during pregnancy. Thromb Haemostas 1984; 52: 124-126
- 43 Chmielewska J, Ranby M, Wiman B. Evidence for a rapid inhibitor to tissue-type plasminogen activator in plasma. Thromb Res 1983; 31: 427-437